Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Blay, J.Y.

Refine Results

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(61 - 80 of 109)

Pages

Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
Consensus nomenclature for CD8(+) T cell phenotypes in cancer
Gastrointestinal Stromal Tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii21, 2014)
Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii113, 2014)
Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii102, 2014)
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Etoposide and Carbo-or Cisplatin Combination Therapy in Refractory or Relapsed Ewing Sarcoma: A Large Retrospective Study
Building a global consensus approach to chordoma: a position paper from the medical and patient community
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials
Classification of current anticancer immunotherapies
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes

Pages